<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.2 20190208//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.2?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7473106</article-id><article-id pub-id-type="pmid">32490731</article-id><article-id pub-id-type="publisher-id">1776161</article-id><article-id pub-id-type="doi">10.1080/22221751.2020.1776161</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of
Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeting SARS-CoV-2 receptors as a means for reducing infectivity and
improving antiviral and immune response: an algorithm-based method for overcoming
resistance to antiviral agents</article-title><alt-title alt-title-type="right-running-head">EMERGING MICROBES AND INFECTIONS</alt-title><alt-title alt-title-type="left-running-head">R. GELMAN ET AL.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gelman</surname><given-names>Ram</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Bayatra</surname><given-names>Areej</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Kessler</surname><given-names>Asa</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><name><surname>Schwartz</surname><given-names>Asaf</given-names></name><xref ref-type="aff" rid="AF1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0802-1220</contrib-id><name><surname>Ilan</surname><given-names>Yaron</given-names></name><xref ref-type="aff" rid="AF1"/><xref ref-type="corresp" rid="cor1"/></contrib><aff id="AF1"><institution>Department of Medicine, Hebrew University-Hadassah Medical
Center</institution>, <city>Jerusalem</city>, <country>Israel</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Yaron Ilan <email xlink:href="ilan@hadassah.org.il">ilan@hadassah.org.il</email><institution>Department of Medicine, Hebrew University-Hadassah Medical
Center</institution>, <city>Jerusalem</city>, <country>Israel</country></corresp><fn id="fn0001-d19e83"><p>First three authors contributed equally</p></fn><fn id="fn0002-d19e85" fn-type="author-notes"><p>Abbreviations: SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; IFN&#x003b1;: S:
spike protein; RAS: renin angiotensin system; Interferon &#x003b1;; IL-6: interleukin 6; ARDS:
acute respiratory distress syndrome; IL-10: interleukin 10; TNF&#x003b1;: tumor necrosis factor
alpha; IFN&#x003b3;: interferon gamma; TLR: Toll Like Receptor; IL-1&#x003b2;: interleukin-1 beta; ACE:
angiotensin-converting enzyme; RBD: receptor-binding domain; TMPRSS2: transmembrane
protease serine 2; S protein: spike glycoprotein; LPS: lipopolysaccharide; COPD: chronic
obstructive pulmonary disease; IL-8: interleukin 8; NF-kappaB: nuclear factor&#x02013;kappa B;
ARB: angiotensin receptor blocker; DPP4: Dipeptidyl peptidase 4; MERS-CoV: Middle
Eastern respiratory syndrome coronavirus; SARS-CoV: Severe Acute Respiratory Syndrome
Coronavirus; NK: natural killer; IGFII-R: insulin growth factor-II receptor; CXC-R4:
C-X-C motif receptor 4; PBMC: peripheral blood mononuclear cells; GRP78:
Glucose-regulated protein 78; ER: endoplasmic reticulum; ATF6: activating transcription
factor 6; PERK: protein kinase RNA-like endoplasmic reticulum kinase; IRE1:
inositol-requiring enzyme 1; SBD: substrate-binding domain; SBD &#x003b2;: substrate binding
domain &#x003b2;; COVID-19: coronavirus disease-19;</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>18</day><month>6</month><year>2020</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2020</year></pub-date><volume>9</volume><issue>1</issue><fpage seq="164">1397</fpage><lpage>1406</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as
Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co.,
Ltd</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="vor">http://creativecommons.org/licenses/by/4.0/</ali:license_ref></license></permissions><self-uri content-type="pdf" xlink:href="TEMI_9_1776161.pdf"/><abstract><title>ABSTRACT</title><p>The ongoing severe acute respiratory syndrome pandemic caused by the novel coronavirus 2
(SARS-CoV-2) is associated with high morbidity and mortality rates, and it has created a
pressing global need for effective antiviral therapies against it. COVID-19 disease
pathogenesis is characterized by an initial virus-mediated phase, followed by
inappropriate hyperactivation of the immune system leading to organ damage. Targeting of
the SARS-CoV-2 viral receptors is being explored as a therapeutic option for these
patients. In this paper, we summarize several potential receptors associated with the
infectivity of SARS-CoV-2 and discuss their association with the immune-mediated
inflammatory response. The potential for the development of resistance towards antiviral
drugs is also presented. An algorithm-based platform to improve the efficacy of and
overcome resistance to viral receptor blockers through the introduction of personalized
variability is described. This method is designed to ensure sustained antiviral
effectiveness when using SARS-CoV-2 receptor blockers.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Coronavirus</kwd><kwd>SARS-COV-2</kwd><kwd>treatment</kwd><kwd>receptors</kwd><kwd>ACE</kwd><kwd>viral resistance</kwd><kwd>DPP4</kwd></kwd-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="94"/><page-count count="10"/></counts></article-meta></front><body><sec sec-type="intro" id="S001"><label>1.</label><title>Introduction</title><p>The ongoing severe acute respiratory syndrome pandemic caused by the coronavirus 2
(SARS-CoV-2), which causes the coronavirus disease (COVID-19), is associated with high
morbidity and mortality rates worldwide [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Two
previous coronaviruses have already previously drawn global attention, by causing
potentially lethal epidemic outbreaks: the severe acute respiratory syndrome coronavirus
(SARS-CoV), and the Middle East respiratory syndrome coronavirus (MERS-CoV) [<xref rid="CIT0002" ref-type="bibr">2</xref>]. Currently, there are no specific antiviral drugs
or vaccines for treatment of COVID-19 [<xref rid="CIT0003" ref-type="bibr">3</xref>].
Moreover, the potential for resistance to antiviral agents, as is common in numerous
viruses, may become a major obstacle for the development of effective therapies against
SARS-CoV-2 [<xref rid="CIT0004" ref-type="bibr">4</xref>].</p><p>In the present paper, we outline the potential targeting of receptors for SARS-CoV-2
therapy. The potential effect of blocking these receptors in the modulation of downstream
immune responses, both in initial and late phases of the disease, is discussed. An
algorithm-based platform to improve the efficacy of and overcome resistance to viral
receptor blockers by introducing personalized variability is presented.</p><sec id="S001-S2001"><label>1.1.</label><title>SARS-CoV-2 pathogenesis, infectivity, and target organ damage</title><p>SARS-CoV-2 infects lung cells after being transmitted via person-to-person transmission,
even while the carrier is asymptomatic [<xref rid="CIT0005" ref-type="bibr">5</xref>]. The
pathogenesis of COVID-19 depends on the interactions between the virus and the immune
system [<xref rid="CIT0006" ref-type="bibr">6</xref>].</p><p>Coronavirus tropism is predominantly determined by interactions between the viral spike
(S) proteins and host receptors [<xref rid="CIT0007" ref-type="bibr">7</xref>]. Cell entry
of coronaviruses requires the binding of the viral S protein to cellular receptors and
depends on S protein priming by host cell proteases [<xref rid="CIT0008" ref-type="bibr">8</xref>]. The spike protein contributes to host receptor binding, cell tropism, and
pathogenesis, and it acts by binding to host receptors on target cells and inducing
endocytosis of virions. This is followed by the fusion of host and viral membranes,
allowing for the penetration of the viral genome into the host cytoplasm. The S protein is
also a target of the host immune system, which adds selective pressures to this
biochemical machinery [<xref rid="CIT0009" ref-type="bibr">9</xref>]. Coronavirus spikes
can recognize a broad range of cell-surface molecules in addition to target receptors,
thereby augmenting coronavirus cellular attachment and entry [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>COVID-19 disease progression follows a two-step process. In the viral infection phase,
cellular infection takes place in various organs via specific receptors [<xref rid="CIT0010" ref-type="bibr">10</xref>]<sans-serif>.</sans-serif> Initially, symptoms
that present are constitutional such as fever, myalgia, and respiratory symptoms including
throat pain, cough, and shortness of breath [<xref rid="CIT0011" ref-type="bibr">11</xref>]. The innate immune response is mediated by interferon &#x003b1; (IFN&#x003b1;) secretion and
characterized by elevated levels of interleukin 6 (IL-6), CRP, and neutrophils, with an
accompanying decrease in lymphocyte count. The virus can hamper IFN production and
downstream signaling, and a dysregulated type I interferon response is part of the
pathogenesis of severe infections [<xref rid="CIT0012" ref-type="bibr">12</xref>].</p><p>The initial viral-infection phase is followed by an inappropriate hyperactivation of the
immune response, involving multiple cytokines and immune cells, which induce
immune-mediated end-organ damage [<xref rid="CIT0012" ref-type="bibr">12</xref>]. In some
patients, the disease progresses to a severe form which most commonly manifests as acute
respiratory distress syndrome (ARDS) followed by respiratory failure, acute myocardial
injury, cardiac dysfunction, shock, and multiple organ failure [<xref rid="CIT0005" ref-type="bibr">5</xref>]. The severe form of the disease is associated with increased
cytokine levels (IL-6, IL-10, and TNF&#x003b1;), lymphopenia (in CD4+ and CD8+ T cells), and
decreased IFN&#x003b3; expression in CD4+ T cells [<xref rid="CIT0013" ref-type="bibr">13</xref>].
Viral binding to the toll like receptor (TLR) promotes pro-IL-1&#x003b2; cleavage by caspase-1,
followed by inflammasome activation and an IL-1&#x003b2; surge that induces lung inflammation,
fever, and fibrosis [<xref rid="CIT0014" ref-type="bibr">14</xref>].</p><p>The adaptive immune response towards SARS-CoV-2 is a Th1 type response, mediated by
cytotoxic T cells (responsible for killing virus-infected cells), and a humoral response
comprising antibody production to neutralize the virus and ultimately protect from the
disease [<xref rid="CIT0015" ref-type="bibr">15</xref>]. A Th1 response is associated with
stronger levels of T cell activity and neutralizing antibodies, leading to recovery, while
a Th2 response may be associated with fatal disease [<xref rid="CIT0016" ref-type="bibr">16</xref>].</p><p>Taken together, the data support the presence of virus-immune system interactions, which
underlie the pathogenesis of COVID-19.</p></sec><sec id="S001-S2002"><label>1.2.</label><title>ACE2 is a SARS-CoV-2 receptor that may affect the antiviral immune response</title><p>The renin-angiotensin system (RAS) is essential for the regulation of organ functions
including those relating to the cardiovascular system, blood pressure, fluid and
electrolyte balance, the kidneys, and the lungs. RAS is also known to exert
tissue-specific local effects associated with hypertension, myocardial injury, heart
failure, diabetes, and inflammatory lung diseases [<xref rid="CIT0017" ref-type="bibr">17</xref>]. RAS and the angiotensin-converting enzyme (ACE) are subjects of interest in
determining the pathophysiology of lung inflammation in numerous disease processes [<xref rid="CIT0018" ref-type="bibr">18</xref>]. Renin secretion from the juxtaglomerular
apparatus of the kidneys in response to a variety of stimuli acts on the circulating
precursor angiotensinogen to generate angiotensin I. The conversion of angiotensin I,
which lacks vasoconstriction properties, to angiotensin II, a potent vasopressor, is due
to the action of ACE [<xref rid="CIT0019" ref-type="bibr">19</xref>]. The modulation of
RAS via ACE inhibition has been a primary strategy in the treatment of hypertension and
heart failure [<xref rid="CIT0019" ref-type="bibr">19</xref>].</p><p>ACE2, a human ACE homologue, is found primarily in the heart, kidneys, and testicular
tissues in humans [<xref rid="CIT0020" ref-type="bibr">20</xref>]. ACE2 has a deceptive
signaling peptide, a metalloprotease active site, and a transmembrane domain, which share
genomic structures with ACE, suggesting that the two genes share a common ancestor. ACE2
is a negative RAS regulator, and ACE/ACE2 imbalance is an important parameter in several
disease processes including lung injuries associated with ARDS [<xref rid="CIT0021" ref-type="bibr">21</xref>,<xref rid="CIT0022" ref-type="bibr">22</xref>].</p><p>ACE2 is a metallopeptidase that serves as a cellular entry point for SARS-CoV and is more
abundantly expressed on the apical surface than the basolateral surface of polarized
airway epithelia, as well as by oral mucosal epithelial cells [<xref rid="CIT0023" ref-type="bibr">23</xref>,<xref rid="CIT0024" ref-type="bibr">24</xref>]. ACE2
expression positively correlates with the differentiation state of epithelia.
Undifferentiated cells expressing low ACE2 levels are poorly infected by SARS-CoV, while
well-differentiated cells expressing high levels are readily infected [<xref rid="CIT0025" ref-type="bibr">25</xref>]. A high affinity between ACE2 and the viral S1 protein domain
of the SARS-CoV S protein has been described. Viral entry into and replication in host
cells depends upon interactions between the viral S protein, and the ACE2 receptor on the
host cell membrane. This is followed by S protein priming of the transmembrane protease
serine 2 (TMPRSS2) [<xref rid="CIT0008" ref-type="bibr">8</xref>,<xref rid="CIT0026" ref-type="bibr">26</xref>].</p><p>The ability of anti-ACE2 antibodies, but not anti-ACE antibodies, to inhibit viral
replication in susceptible cells has been shown in a dose-dependent manner, which supports
a substantial contribution of ACE2 to the efficiency of SARS-CoV replication [<xref rid="CIT0023" ref-type="bibr">23</xref>]. Attenuation of RAS activity protects the lungs
and is dependent on ACE2 expression. By deregulation of this lung-protective pathway, the
virus is thought to exhibit higher lethality [<xref rid="CIT0027" ref-type="bibr">27</xref>]. ACE2 is also expressed by gastrointestinal epithelial cells, suggesting
that SARS-CoV-2 can actively infect and replicate in the gastrointestinal tract [<xref rid="CIT0028" ref-type="bibr">28</xref>].</p><p>There are multiple similarities between SARS-CoV-2 and SARS-CoV. The three dimensional
structures of the spike protein receptor-binding domain of both viruses are almost
identical, with a high degree of homology and 76% amino-acid sequence identity similarity
[<xref rid="CIT0029" ref-type="bibr">29</xref>]. Like other coronaviruses, SARS-CoV-2
uses the S protein as the main interacting protein with host cell receptors, including the
SARS-CoV receptor ACE2 for entry, and the serine protease TMPRSS2 for S protein priming
[<xref rid="CIT0016" ref-type="bibr">16</xref>]. A TMPRSS2 inhibitor inhibited the viral
entry and sera from convalescent SARS patients cross-neutralized SARS-CoV-2 S-driven entry
[<xref rid="CIT0008" ref-type="bibr">8</xref>]. SARS-CoV, and presumably SARS-CoV-2,
leads to downregulation of the ACE2 receptor, but not the ACE receptor, via binding of the
S protein with ACE2. This leads to viral entry and replication, and potentially to severe
lung injury [<xref rid="CIT0027" ref-type="bibr">27</xref>]. The receptor-binding domain
(RBD) of the SARS-CoV-2 S protein binds to ACE2 receptors, and it manifests a higher ACE2
binding affinity than that of SARS-CoV, and it could block the binding and attachment of
SARS-CoV-2 RBD to ACE2-expressing cells inhibiting their infection to the host cells
[<xref rid="CIT0030" ref-type="bibr">30</xref>].</p><p>Patients with cardiovascular and respiratory diseases such as hypertension, heart
failure, and obstructive or inflammatory lung disease are more susceptible to SARS-CoV-2
infection [<xref rid="CIT0031" ref-type="bibr">31</xref>]. This may be related to
differences in RAS activation and ACE2 expression, in addition to upregulation of the
receptor in the lungs in response to medical treatment that contributes to RAS inhibition
[<xref rid="CIT0032" ref-type="bibr">32</xref>,<xref rid="CIT0033" ref-type="bibr">33</xref>].</p><p>Glutamyl aminopeptidase (ENPEP) is a member of the M1 family of endopeptidases, which are
membrane type II zinc-containing endopeptidases. It is involved in the catabolic pathway
of RAS-formed angiotensin III, and it has been proposed as another potential receptor for
human coronaviruses [<xref rid="CIT0034" ref-type="bibr">34</xref>].</p><p>Potential therapeutic approaches have been proposed to target various steps in the viral
infectious process, including a SARS-CoV-2 S-protein-based vaccine, a TMPRSS2 inhibitor
aiming to block the priming of the viral S protein, an anti-ACE2 antibody to block the
surface receptor, and a soluble ACE2 analogue which competitively binds with SARS-CoV-2 to
slow viral entry into cells and decrease viral spread [<xref rid="CIT0027" ref-type="bibr">27</xref>].</p><p>ACE2 also plays a role in immune function and may be linked to immune responses
associated with COVID-19 pathogenesis. RAS is associated with inflammation and fibrosis,
and the RAS axis is composed of ACE2 and angiotensin-(1-7), while the Mas receptor exerts
opposite effects in terms of inflammatory responses and tissue fibrosis. Viral respiratory
infections such as influenza strains, the respiratory syncytial virus, and SARS-CoV-2 can
mediate lung inflammation and injury via ACE2 dysregulation [<xref rid="CIT0035" ref-type="bibr">35</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref>].</p><p>Downregulation of ACE2 activity in mice treated with an ACE2 inhibitor prior to
instilling lipopolysaccharide (LPS) was shown. It-facilitated neutrophil infiltration
parallel to ACE2 reduction, via reduced ACE2 inhibition of des-Arg9 bradykinin
(DABK)/bradykinin receptor B1 (BKB1R) axis signaling. This led to pro-inflammatory
chemokine expression, increased neutrophil infiltration, and exaggerated levels of lung
inflammation and injury [<xref rid="CIT0037" ref-type="bibr">37</xref>]. These effects
affect additional inflammatory processes in the lungs, including pulmonary fibrosis,
chronic obstructive pulmonary disease (COPD), asthma, and acute lung injury due to
potentiation of pro-fibrotic and pro-inflammatory cytokines and stimulation of angiotensin
II receptors. These processes are associated with the expression of pro-inflammatory
mediators, such as interleukin(IL)-8/cytokine-induced neutrophil chemoattractant-3 and
IL-6 [<xref rid="CIT0038" ref-type="bibr">38</xref>].</p><p>The anti-inflammatory and anti-fibrogenic effects of the ACE2/Ang-(1-7)/Mas axis are
linked to reduced cytokine release and the inhibition of fibrosis-associated signaling
pathways in models of atherosclerosis, cerebral ischemia, obesity, chronic kidney disease,
liver disease, and asthma [<xref rid="CIT0039" ref-type="bibr">39</xref>]. Loss of ACE2 is
associated with increased neutrophil, macrophage, and T-cell infiltration in a model of
acute kidney injury. MRNA levels relating to pro-inflammatory cytokines, IL-1&#x003b2;, IL-6,
TNF&#x003b1;, the macrophage inflammatory protein 2, and the monocyte chemoattractant protein-1,
were increased in ACE2 knockout (KO) mice. Decreased ACE2 expression is associated with
increased apoptosis and oxidative stress [<xref rid="CIT0040" ref-type="bibr">40</xref>].
Amelioration of sepsis-induced-lung injury is mediated via regulation of the
ACE2/Ang-(1-7)/Mas axis and inhibition of the MAPK/NF-kappaB inflammatory signaling
pathways [<xref rid="CIT0041" ref-type="bibr">41</xref>]. Treatment with an angiotensin I
receptor blocker prevented angiotensin II-mediated aortic profilin-1 expression, and
inflammation [<xref rid="CIT0042" ref-type="bibr">42</xref>].</p><p>Clinical data suggested that application of ACE inhibitors and ARB contribute to the
clinical outcomes of COVID-19 patients with hypertension. Patients receiving ACEI or ARB
therapy had a lower rate of severe diseases, a trend toward a lower level of IL-6 in
peripheral blood, and decreased peak viral load [<xref rid="CIT0043" ref-type="bibr">43</xref>]. Among hospitalized COVID-19 patients with hypertension, the use of these
drugs was associated with lower risk of all-cause mortality [<xref rid="CIT0044" ref-type="bibr">44</xref>].</p><p>These data suggest that, under some conditions, worsening of inflammation occurs using
ACE2 blockers, which may be beneficial in early stages of SARS-CoV-2 infections. The
effects of these blockers during late disease phases, in which the target organ damage is
mediated by inflammatory pathways, remain to be shown.</p></sec><sec id="S001-S2003"><label>1.3.</label><title>Dipeptidyl peptidase 4 is a coronavirus receptor, which may also be associated with
the antiviral immune response</title><p>Dipeptidyl peptidase 4 (DPP4), also known as CD26, is a 110&#x02005;kDa transmembrane
glycoprotein expressed on the surface of a wide variety of epithelial cells and some
lymphocytes. It acts as a peptidase, cleaving N-terminal dipeptides and degrading numerous
substances including hormones, neuropeptides, chemokines, and cytokines. The most notable
of these are the incretin hormones, which participate in glucose metabolism [<xref rid="CIT0045" ref-type="bibr">45</xref>].</p><p>DPP4 is uncommon in surface epithelial cells from the nasal cavities to the conducting
airways, with a somewhat increased incidence in the distal airways. It has been detected
in mononuclear leukocytes and serous cells of submucosal glands [<xref rid="CIT0046" ref-type="bibr">46</xref>]. In the lungs, it is present on the surfaces of non-ciliated
bronchial epithelial cells, on type I and II cells, alveolar macrophages, and on vascular
endothelial cells, lymphatics, and pleural mesothelia. Patients with chronic lung disease
manifest increased DPP4 immunostaining in alveolar epithelia, type I and II alveolar
cells, and alveolar macrophages [<xref rid="CIT0046" ref-type="bibr">46</xref>].</p><p>DPP4 is a known receptor for MERS-CoV, and antibodies against it inhibit hCoV-EMC
infection of primary human bronchial epithelial cells and Huh-7 cells [<xref rid="CIT0047" ref-type="bibr">47</xref>].</p><p>A study that examined the SARS-CoV-2 S protein suggested that its S1 domain, which
presumably serves as the viral binding site, interacts with DPP4 [<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref>]. SARS-CoV-2 is
thought to have a zoonotic origin prior to person-to-person transmission, and it has a
high genetic similarity to SARS-CoV and MERS-CoV, which both originated in bats [<xref rid="CIT0050" ref-type="bibr">50</xref>,<xref rid="CIT0051" ref-type="bibr">51</xref>].
The DPP4 protein &#x02018;s amino acid sequence is highly conserved across different species,
including bats. In vitro expression of human and bat DPP4 in previously non-susceptible
cells without previous DPP4 expression subsequently enabled infection of those cells by
MERS-CoV. Serious adverse outcomes in patients with SARS-CoV-2 have been described more
frequently in patients with COPD comorbidity [<xref rid="CIT0052" ref-type="bibr">52</xref>]. Smokers, and subjects with COPD, express higher rates of DPP4 [<xref rid="CIT0053" ref-type="bibr">53</xref>].</p><p>DPP4 is also expressed on immune cells including T and B lymphocytes, activated natural
killer (NK) cells, and myeloid cells. It plays a role in T-cell mediated immune responses,
and contributes to T cell development, maturation, differentiation and activation [<xref rid="CIT0054" ref-type="bibr">54</xref>]. DPP4 is involved in T-cell co-stimulatory
activation via its association with adenosine deaminase (ADA), caveolin-1, the caspase
recruitment domain-containing membrane-associated guanylate kinase protein-1 (CARMA-1),
CD45, the mannose-6-phosphate/insulin growth factor-II receptor (M6P/IGFII-R), and the
C-X-C motif receptor 4 (CXC-R4). DPP4 mediates co-stimulation in human CD8+ lymphocytes,
contributing to acquired immune responses, and its role in T-cell immunity is attributed
to its peptidase activity and ability to serve as a receptor for numerous molecules,
including memory antigens [<xref rid="CIT0055" ref-type="bibr">55</xref>].</p><p>DPP4 inhibitors modulate TCR signaling, inhibit the proliferation of CD4+ and CD8+
lymphocytes, and suppress antigen-stimulated CD4+ T-cell clone secretion of IFN-&#x003b3;, TNF-&#x003b1;,
and IL-4 in a dose-dependent manner [<xref rid="CIT0056" ref-type="bibr">56</xref>]. DPP4
is also a positive regulator of B cell activation, and its inhibitors suppress that
activation via suppression of DNA synthesis in mitogenic active B cells [<xref rid="CIT0057" ref-type="bibr">57</xref>].</p><p>The interaction of the MERS-CoV S protein with DPP4 initiates signals that suppress
macrophage activation [<xref rid="CIT0058" ref-type="bibr">58</xref>]. Infection of
macrophages with particles pseudotyped with the MERS-CoV S protein also suppresses
macrophage responses, by reducing their capacity to produce TNF&#x003b1; and IL-6 in naive and
LPS-activated THP-1 macrophages, and by augmenting the LPS-induced production of the
immunosuppressive cytokine IL-10. The MERS-CoV S protein induces the expression of a
negative regulator of TLR signaling, IRAK-M, and of a transcriptional repressor, PPAR&#x003b3;
[<xref rid="CIT0058" ref-type="bibr">58</xref>].</p><p>Sitagliptin is a DPP4 inhibitor used for treatment of diabetes mellitus. It can inhibit
proliferation of phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMC)
from healthy volunteers, decreased CD26 expression, and reduced the proportions of Th1,
Th2, and Th17 lymphocytes [<xref rid="CIT0059" ref-type="bibr">59</xref>]. Clinical
treatment with sitagliptin reduced the number of circulating CD4+ T cells, Th17
lymphocytes, and regulatory T cells, and increased the number of circulating CD34 CXCR4
cells by approximately a factor of two in patients with type 2 diabetes [<xref rid="CIT0060" ref-type="bibr">60</xref>]. Inhibition of DPP4 by siRNA or sitagliptin
diminished the effects of the MERS-CoV S protein on IRAK-M, PPAR&#x003b3; and IL-10, supporting
its immunosuppressive effects [<xref rid="CIT0058" ref-type="bibr">58</xref>].</p><p>The data suggest that blocking DPP4 receptors may have potential benefits in modulation
of the COVID-19 immune response, both in early and late phases of the disease. Sitagliptin
has been proposed as a potential therapy for patients infected with SARS-CoV-2. <xref rid="F0001" ref-type="fig">Figure 1</xref>A shows a schematic representation of the
effects of blocking ACE2 and DPP4 receptors on viral infectivity, and on immunomodulation
of the inappropriate immune hyperactivation that induces the organ damage during the
disease. <fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p><bold>A.</bold> Potential targets for treatment of SARS-CoV-2 infection at the
receptor level affecting downstream immune responses to the virus. <bold>B.</bold>
The introduction of personalized variability to counter resistance to antiviral
treatments. Regular, fixed dosing using an antiviral agent with robust and rapid
effects is expected to lead to viral clearance, while fixed dosing regimens of
moderately effective drugs may lead to drug resistance, viral persistence, an
augmented hyperactivation of the immune system, and severe disease. The introduction
of an algorithm-based dosing method based on quantified variability patterns derived
from disease and host parameters improves the response to antiviral drugs.</p></caption><alternatives><graphic specific-use="web-only" content-type="color" xlink:href="TEMI_A_1776161_F0001_OC"/><graphic specific-use="print-only" content-type="black-white" xlink:href="TEMI_A_1776161_F0001_PB"/></alternatives></fig></p></sec><sec id="S001-S2004"><label>1.4.</label><title>The SARS-CoV-2 spike-host cell receptor GRP78 binding site</title><p>The glucose-regulated protein 78 (GRP78) is an endoplasmic reticulum (ER) chaperone that
plays a role in viral entry [<xref rid="CIT0061" ref-type="bibr">61</xref>,<xref rid="CIT0062" ref-type="bibr">62</xref>]. It is involved in protein folding and
assembly, translocation of newly synthesized polypeptides, degradation of misfolded
proteins, and the maintenance of ER homeostasis [<xref rid="CIT0063" ref-type="bibr">63</xref>]. GRP78 is a regulator of ER stress due to its role in the unfolded protein
response pathway, and it has also been detected in the mitochondria, nucleus, cytosol, and
plasma membrane. It is associated with cell surface regulation of signaling and cellular
homeostasis [<xref rid="CIT0064" ref-type="bibr">64</xref>]. In the ER lumen, it binds to
and inactivates three enzymes responsible for cell death or differentiation, including
activating transcription factor 6 (ATF6), protein kinase RNA-like endoplasmic reticulum
kinase (PERK), and the inositol-requiring enzyme 1 (IRE1) [<xref rid="CIT0086" ref-type="bibr">86</xref>]. Above a certain threshold of accumulated unfolded proteins,
GRP78 releases and activates ATF6, PERK, and IRE1, leading to the inhibition of protein
synthesis and enhancement of protein refolding [<xref rid="CIT0064" ref-type="bibr">64</xref>]. Overexpression of GRP78 is initiated by cellular exposure to stress, which
increases the likelihood that it will escape ER retention and translocate to the cell
membrane. Once there, its substrate-binding domain (SBD) can be recognized by the virus,
which allows viral entry into the cell. GRP78 inhibits hepatitis B virus replication by
reducing viral production and protein secretion [<xref rid="CIT0065" ref-type="bibr">65</xref>].</p><p>GRP78 is abundantly expressed by epithelial cells of the bronchus, bronchiole, and
alveolus. Double immunostaining of DPP4 and GRP78 demonstrated the co-localization of DPP4
and GRP78 in the epithelial cells lining the human airways. GRP78 augments viral entry to
susceptible cells in the presence of the host cell receptor DPP4 [<xref rid="CIT0008" ref-type="bibr">8</xref>]. The co-localization of DPP4 and GRP78 to the epithelial cell
apical sides further supports the notion that GRP78 facilitates MERS-CoV entry or
attachment. GRP78 assists in the attraction of virus particles to the cell surface,
increasing the likelihood of receptor-mediated MERS-CoV and bat coronavirus HKU9
(bCoVHKU9) viral entry. MERS-CoV infection results in an up-regulation of GRP78 on the
cell surface, which increases viral attachment and enhances viral entry into infected
cells [<xref rid="CIT0007" ref-type="bibr">7</xref>].</p><p>Infections by certain coronaviruses, including the infectious bronchitis virus and
SARS-CoV, induce ER stress leading to GRP78 expression on the cell surface [<xref rid="CIT0066" ref-type="bibr">66</xref>,<xref rid="CIT0067" ref-type="bibr">67</xref>].
The SARS-CoV S protein induces transcriptional activation of GRP78, and a substantial
amount of S protein accumulates in the ER. The expression of the S protein exerts
different effects on the three major signaling pathways of the unfolded protein response
(UPR), inducing GRP78 through PKR-like ER kinase [<xref rid="CIT0068" ref-type="bibr">68</xref>].</p><p>A recent study proposed that the SARS-CoV-2 S protein binds to the GRP78 cell-surface
receptor [<xref rid="CIT0069" ref-type="bibr">69</xref>]. The SARS-CoV-2 S protein has
been modelled using its counterpart, the SARS-CoV spike protein. Pep42 is a cyclic peptide
that binds to GRP78 at the surface of cancer cells. Sequence and structural alignments
have shown that four regions of the S protein have sequence and physicochemical
similarities to Pep42. Protein&#x02013;protein docking studies have shown that the four S protein
regions fit tightly in the GRP78 substrate binding domain &#x003b2; (SBD &#x003b2;). The docking pose
showed an association of the SBD &#x003b2; of GRP78 and the receptor-binding domain of the virus S
protein in recognition of the host cell receptor. Region IV predicted a high binding
affinity, and it has been proposed as a potential therapeutic target [<xref rid="CIT0069" ref-type="bibr">69</xref>].</p></sec><sec id="S001-S2005"><label>1.5.</label><title>Resistance to antiviral agents is a major obstacle to sustainable therapeutic
effectiveness</title><p>Similarly to SARS-CoV and MERS-CoV, there is no clinically proven specific antiviral
agent available to treat SARS-CoV-2 infections. Several potential therapies, including the
repurposing of existing antiviral agents, have been proposed [<xref rid="CIT0070" ref-type="bibr">70</xref>]. The broad-spectrum antiviral remdesivir and chloroquine have
been effective for viral control <italic>in vitro</italic>. Remdesivir is an
adenosine analogue which targets the RNA-dependent RNA polymerase and blocks viral RNA
synthesis, and it has shown antiviral activity against a wide array of RNA viruses
including SARS/MERS-CoV. Other nucleoside analogues, such as favipiravir, ribavirin and
galidesivir have also been suggested as potential treatments [<xref rid="CIT0070" ref-type="bibr">70</xref>,<xref rid="CIT0071" ref-type="bibr">71</xref>]. Studies
supporting some role for broad-spectrum antiviral remdesivir and chloroquine in COVID-19
were published [<xref rid="CIT0072" ref-type="bibr">72&#x02013;81</xref>].</p><p>Prolonged exposure to antiviral drugs and ongoing viral replication are key factors in
the development of drug resistance, which may manifest as persistent or increasing viremia
or severe disease resulting from progressive viral infection. In cases where the treatment
course is effective and viral fitness is impaired sufficiently, no viral genomes will be
successfully replicated. However, in conditions where the treatment is not as effective
and some genomes replicate, selective pressures may result in rapid adaptation leading to
viral resistance [<xref rid="CIT0082" ref-type="bibr">82</xref>].</p><p>Both host and viral factors are linked to the development of resistance, which involves
mechanisms of viral replication, genomic inference, or selective pressures that result in
viral adaptation associated with high rates of viral mutations. Antiviral resistance is
linked to high mutation and recombination rates, demographic histories of transmission,
compartmentalization, and selective forces incurred during viral adaptation to drugs
[<xref rid="CIT0082" ref-type="bibr">82</xref>].</p><p>Both receptor-level and post-receptor-level resistance may occur. Antiviral inhibition of
the viral replication cycle can occur at the level of virion inhibition, adsorption, viral
penetration, viral uncoating, genome replication, or the release of mature virions [<xref rid="CIT0083" ref-type="bibr">83</xref>]. The process of entry into a host cell is
important for the life cycle of most viruses, and broad-spectrum antiviral approaches
which target host cell proteins and pathways are being used. Following the attachment to
the cell surface or receptors, many viruses induce changes to environmental conditions,
such as pH, interactions with a cellular receptor, or modulate the activity of proteolytic
enzymes which leads to conformational changes in key proteins that mediate cell membrane
penetration [<xref rid="CIT0084" ref-type="bibr">84</xref>].</p><p>Models have been developed to describe the development of influenza resistance using
semi-stochastic simulations which determine the emergence of resistant mutants during
infection, in the presence or absence of antiviral agents. A mismatch between surface
proteins and internal RNA correlated with a reduced likelihood of the appearance of
drug-resistant mutants. Late occurrence of mutants was thought to be because the mismatch
provided an option to prevent the propagation of the mutation. The immune response may
also lower the probability of drug-resistant infection [<xref rid="CIT0085" ref-type="bibr">85</xref>].</p><p>Resistance against protease or polymerase inhibitors used for the treatment of hepatitis
C viral infections have been linked to a lower genetic barrier to resistance, and they can
be achieved through a single or a small number of mutations. Combinations such as
ledipasvir and sofosbuvir, which have high genetic barriers to resistance, show little
cross-resistance between the two drugs. Acyclovir and its related analogues used against
herpes viruses are nucleoside inhibitors, against which resistance mutations are known
that affect either a thymidine kinase required for prodrug activation by phosphorylation,
or the DNA polymerase. HIV reverse transcriptase is highly error prone, leading to a high
rate of nucleotide substitutions, increased population diversity, and frequent resistance
mutations and drug resistance. Combination therapies reduce the incidence of resistance
without known cross-resistance mutations [<xref rid="CIT0086" ref-type="bibr">86</xref>].</p><p>The overcoming of drug resistance, especially under conditions where the drugs are unable
to provide rapid and complete viral clearance, is a major obstacle for improving the
morbidity and mortality rates caused by numerous viruses. The use of an integrative
antiviral drug repurposing methodology has been proposed to implement a pharmacology-based
platform able to shorten the time to develop anti-SARS-CoV-2 drugs [<xref rid="CIT0087" ref-type="bibr">87</xref>]. However, these may not only fail to prevent resistance, but
may actually promote it due to the relatively moderate antiviral effects of these
agents.</p></sec><sec sec-type="intro" id="S001-S2006"><label>1.6.</label><title>The introduction of variability into therapy to overcome resistance at the receptor
level</title><p>Biological systems are characterized by an inherent variability, which can be viewed as a
property of causal processes, contributing to their function. The stochastic behaviour of
these systems typifies their dynamic behaviour in response to internal and external
triggers. Intrinsic stochasticity has been described for intracellular pathways [<xref rid="CIT0088" ref-type="bibr">88</xref>]. Intra- and inter-subject biological
variability has been described at the cellular organelle level, as well as for whole
organs [<xref rid="CIT0088" ref-type="bibr">88</xref>]. Variability also underlies
responses to disease-inducing triggers and also to the effect of drugs [<xref rid="CIT0089" ref-type="bibr">89</xref>].</p><p>Individual tolerance to drugs is a random variable that derives from multiple genetic and
environmental factors, which suggests that deterministic equations are not suitable for
modelling it. Variability of the treatment response has been attributed to
pharmacogenomic- and pharmacodynamic-based drug metabolism parameters, but the
heterogeneity in the responses cannot be attributed solely to these factors [<xref rid="CIT0090" ref-type="bibr">90</xref>]. Complex intracellular drug-target and
drug-receptor interactions have been described. Non-specific interactions slow the
incorporation kinetics of DNA-binding drugs, and have been attributed to irregular drug
diffusion in cells. In humans, marked intra-patient variability in drug serum levels
between days has been described [<xref rid="CIT0091" ref-type="bibr">91</xref>]. The
unpredictability of drug effectiveness is partly associated with the dynamicity and
continuously changing rules by which these systems function. Dosing regimens of drugs,
which are based on regular fixed schedules, have been proposed to be incompatible with the
physiological variability by which these systems operate, leading to primary or secondary
loss of response [<xref rid="CIT0092" ref-type="bibr">92</xref>,<xref rid="CIT0093" ref-type="bibr">93</xref>].</p><p>Chronic anti-TNFs therapy is associated with high rates of drug response loss. Dosage
escalations and reductions, as well as drug holidays, are used in real-world settings.
Intermittent dosing with drug holidays has shown clinical benefits while helping to
minimize drug exposure and potential adverse effects. In a prospective trial of patients
with inflammatory bowel disease, irregular dosing reduced the loss of response compared to
regular fixed dosing [<xref rid="CIT0094" ref-type="bibr">94</xref>].</p><p>Antiviral resistance at the receptor or post-receptor levels may be overcome by the
implementation of personalized variability patterns in treatment regimens. A
patient-tailored approach, which implements personalized variability patterns into
treatment algorithms, has been proposed to improve the treatment sustainability. Patterns
of variability can be quantified based on host and disease-related variability patterns,
immune tests, genetic profiling, chronotherapy, heart rate variability, and additional
parameters [<xref rid="CIT0092" ref-type="bibr">92</xref>,<xref rid="CIT0093" ref-type="bibr">93</xref>]. Algorithm-controlled treatment regimens are now being used
in several clinical trials for overcoming drug resistance (NCT03843697; NCT03747705).</p><p>A similar platform has been proposed to ensure sustained effects of receptor-targeted
therapies for SARS-CoV-2 infections. <xref rid="F0001" ref-type="fig">Figure 1</xref>B
shows a schematic representation of the effect of the introduction of personalized
variability as a counter to antiviral drug resistance. Regular, fixed dosing using an
antiviral agent with robust and rapid effects is expected to aid viral clearance and
recovery. On the other hand, fixed dosing with a moderately effective antiviral agent may
lead to viral resistance and persistent infection. Viral persistence is expected to
further augment the immune hyper-activation, leading to worsening of disease severity. The
introduction of an algorithm-based variable treatment approach, which quantifies disease
and host-related personalized patterns, can overcome drug resistance and improve treatment
responses.</p></sec></sec><sec id="S002"><label>2.</label><title>Conclusion</title><p>In summary, the high morbidity and mortality rates in patients with COVID-19, and the lack
of effective treatments, make them a worldwide challenge. Targeting of potential receptors
has been proposed to develop receptor-targeted therapies against the virus. These blockers
have the potential both to reduce infectivity and to counter the inappropriate
over-activation of the immune system that is responsible for end organ damage. As the
likelihood of developing a powerful agent, which can rapidly clear the virus, is low, drug
resistance is a major obstacle for drug development. Administration of antivirals using an
algorithm-regulated regimen can improve the efficacy of these therapies, preventing the
development of resistance and ensuring sustained effects. Future clinical trials will
explore the effect of using these personalized algorithms to improve the clinical effects of
antiviral agents.</p></sec></body><back><sec sec-type="COI-statement" id="S003"><title>Disclosure statement</title><p>YI is the founder of Oberon Sciences and is a consultant for Teva, ENZO, Protalix, Betalin
Therapeutics, Immuron, SciM, Natural Shield, Tiziana Pharma, Plantylight, and Exalenz
Bioscience.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omer</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Malani</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Del Rio</surname><given-names>C.</given-names></name></person-group>
<article-title>The COVID-19 pandemic in the US: a clinical Update</article-title>.
<source>JAMA</source>.
<year>2020</year>;<volume>323(18)</volume>:<fpage>1767</fpage>&#x02013;<lpage>1768</lpage>.</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>XL</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>XG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat
origin</article-title>. <source>Nature</source>.
<year>2020</year>;<volume>579</volume>:<fpage>270</fpage>&#x02013;<lpage>273</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmid">32015507</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Monogue</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Jodlowski</surname><given-names>TZ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a
review</article-title>. <source>JAMA</source>.
<year>2020</year>;<volume>323(18)</volume>:<fpage>1824</fpage>&#x02013;<lpage>1836</lpage>.</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mason</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Devincenzo</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Toovey</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Comparison of antiviral resistance across acute and chronic viral
infections</article-title>. <source>Antiviral Res</source>.
<year>2018</year>;<volume>158</volume>:<fpage>103</fpage>&#x02013;<lpage>112</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.020</pub-id><pub-id pub-id-type="pmid">30086337</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2
pneumonia in Wuhan, China: a single-centered, retrospective, observational
study</article-title>. <source>Lancet Respir Med</source>.
<year>2020</year>;<volume>8(5)</volume>:<fpage>475</fpage>&#x02013;<lpage>481</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id><pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Geng</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Molecular immune pathogenesis and diagnosis of COVID-19</article-title>.
<source>J Pharm Anal</source>.
<year>2020</year>;<volume>10(2)</volume>:<fpage>102</fpage>&#x02013;<lpage>108</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.jpha.2020.03.001</pub-id><pub-id pub-id-type="pmid">32282863</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both
can utilize GRP78 for attachment onto host cells</article-title>. <source>J Biol
Chem</source>.
<year>2018</year>;<volume>293</volume>:<fpage>11709</fpage>&#x02013;<lpage>11726</lpage>. doi:
<pub-id pub-id-type="doi">10.1074/jbc.RA118.001897</pub-id><pub-id pub-id-type="pmid">29887526</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kleine-Weber</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Schroeder</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is Blocked by a
clinically proven protease inhibitor</article-title>. <source>Cell</source>.
<year>2020</year>;<volume>181</volume>:<fpage>271</fpage>&#x02013;<lpage>280</lpage>.
<comment>e8</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigrist</surname><given-names>CJ</given-names></name>, <name name-style="western"><surname>Bridge</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Le Mercier</surname><given-names>P.</given-names></name></person-group>
<article-title>A potential role for integrins in host cell entry by
SARS-CoV-2</article-title>. <source>Antiviral Res</source>.
<year>2020</year>;<volume>177</volume>:<fpage>104759</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104759</pub-id><pub-id pub-id-type="pmid">32130973</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prompetchara</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Ketloy</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Palaga</surname><given-names>T.</given-names></name></person-group>
<article-title>Immune responses in COVID-19 and potential vaccines: lessons learned from
SARS and MERS epidemic</article-title>. <source>Asian Pac J Allergy Immunol</source>.
<year>2020</year>;<volume>38</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32105090</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grasselli</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zangrillo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zanella</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Baseline Characteristics and outcomes of 1591 patients infected With
SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy</article-title>.
<source>JAMA</source>.
<year>2020</year>;<volume>323(16)</volume>:<fpage>1574</fpage>&#x02013;<lpage>1581</lpage>. doi:
<pub-id pub-id-type="doi">10.1001/jama.2020.5394</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L.</given-names></name></person-group>
<article-title>SARS-CoV-2: virus dynamics and host response</article-title>.
<source>Lancet Infect Dis</source>.
<year>2020</year>;<volume>20(5)</volume>:<fpage>515</fpage>&#x02013;<lpage>516</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/S1473-3099(20)30235-8</pub-id><pub-id pub-id-type="pmid">32213336</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rokni</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ghasemi</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Tavakoli</surname><given-names>Z.</given-names></name></person-group>
<article-title>Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran:
comparison with SARS and MERS</article-title>. <source>Rev Med Virol</source>.
<year>2020</year>;<volume>30(3)</volume>:<fpage>e2107</fpage>.<pub-id pub-id-type="pmid">32267987</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ronconi</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Caraffa</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung
inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory
strategies</article-title>. <source>J Biol Regul Homeost Agents</source>.
<year>2020</year>;<volume>34(2):1</volume>.</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sidney</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A sequence homology and Bioinformatic approach Can Predict Candidate
targets for immune responses to SARS-CoV-2</article-title>. <source>Cell Host
Microbe</source>.
<year>2020</year>;<volume>27</volume>:<fpage>671</fpage>&#x02013;<lpage>680</lpage>.
<comment>e2</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2020.03.002</pub-id><pub-id pub-id-type="pmid">32183941</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lei</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its
immune cross-reactivity with SARS-CoV</article-title>. <source>Nat Commun</source>.
<year>2020</year>;<volume>11</volume>:<fpage>1620</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmid">32221306</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>H.</given-names></name></person-group>
<article-title>Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung
disease</article-title>. <source>Shock</source>.
<year>2016</year>;<volume>46</volume>:<fpage>239</fpage>&#x02013;<lpage>248</lpage>. doi:
<pub-id pub-id-type="doi">10.1097/SHK.0000000000000633</pub-id><pub-id pub-id-type="pmid">27082314</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sodhi</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Pulmonary epithelial TLR4 activation leads to lung injury in Neonatal
Necrotizing Enterocolitis</article-title>. <source>J Immunol</source>.
<year>2016</year>;<volume>197</volume>:<fpage>859</fpage>&#x02013;<lpage>871</lpage>. doi:
<pub-id pub-id-type="doi">10.4049/jimmunol.1600618</pub-id><pub-id pub-id-type="pmid">27307558</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Sturrock</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Riordan</surname><given-names>JF</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Ace revisited: a new target for structure-based drug
design</article-title>. <source>Nat Rev Drug Discovery</source>.
<year>2003</year>;<volume>2</volume>:<fpage>891</fpage>&#x02013;<lpage>902</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrd1227</pub-id><pub-id pub-id-type="pmid">14668810</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donoghue</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Baronas</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
converts angiotensin I to angiotensin 1-9</article-title>. <source>Circ Res</source>.
<year>2000</year>;<volume>87</volume>:<fpage>E1</fpage>&#x02013;<lpage>E9</lpage>. doi: <pub-id pub-id-type="doi">10.1161/01.RES.87.5.e1</pub-id><pub-id pub-id-type="pmid">10969042</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kuba</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Angiotensin-converting enzyme 2 protects from severe acute lung
failure</article-title>. <source>Nature</source>.
<year>2005</year>;<volume>436</volume>:<fpage>112</fpage>&#x02013;<lpage>116</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/nature03712</pub-id><pub-id pub-id-type="pmid">16001071</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jia</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Look</surname><given-names>DC</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>ACE2 receptor expression and severe acute respiratory syndrome coronavirus
infection depend on differentiation of human airway epithelia</article-title>. <source>J
Virol</source>.
<year>2005</year>;<volume>79</volume>:<fpage>14614</fpage>&#x02013;<lpage>14621</lpage>. doi:
<pub-id pub-id-type="doi">10.1128/JVI.79.23.14614-14621.2005</pub-id><pub-id pub-id-type="pmid">16282461</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Vasilieva</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS
coronavirus</article-title>. <source>Nature</source>.
<year>2003</year>;<volume>426</volume>:<fpage>450</fpage>&#x02013;<lpage>454</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/nature02145</pub-id><pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuba</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Imai</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS
coronavirus-induced lung injury</article-title>. <source>Nat Med</source>.
<year>2005</year>;<volume>11</volume>:<fpage>875</fpage>&#x02013;<lpage>879</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/nm1267</pub-id><pub-id pub-id-type="pmid">16007097</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of
oral mucosa</article-title>. <source>Int J Oral Sci</source>.
<year>2020</year>;<volume>12</volume>:<fpage>8</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41368-020-0074-x</pub-id><pub-id pub-id-type="pmid">32094336</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukassen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chua</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Trefzer</surname><given-names>T</given-names></name>, <etal>et al.</etal></person-group>
<article-title>SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial
transient secretory cells</article-title>. <source>EMBO J</source>.
<year>2020</year>;<volume>39(10)</volume>:<fpage>e105114</fpage>.<pub-id pub-id-type="pmid">32246845</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular
mechanisms and potential therapeutic target</article-title>. <source>Intensive Care
Med</source>.
<year>2020</year>;<volume>46</volume>:<fpage>586</fpage>&#x02013;<lpage>590</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/s00134-020-05985-9</pub-id><pub-id pub-id-type="pmid">32125455</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Lui</surname><given-names>RN</given-names></name>, <name name-style="western"><surname>Sung</surname><given-names>JJ.</given-names></name></person-group>
<article-title>Covid-19 and the digestive system</article-title>. <source>J Gastroenterol
Hepatol</source>.
<year>2020</year>;<volume>35(5)</volume>:<fpage>744</fpage>&#x02013;<lpage>748</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/jgh.15047</pub-id><pub-id pub-id-type="pmid">32215956</pub-id></mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and
modeling of its spike protein for risk of human transmission</article-title>.
<source>Sci China Life Sci</source>.
<year>2020</year>;<volume>63</volume>:<fpage>457</fpage>&#x02013;<lpage>460</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/s11427-020-1637-5</pub-id><pub-id pub-id-type="pmid">32009228</pub-id></mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W</given-names></name>, <name name-style="western"><surname>He</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Characterization of the receptor-binding domain (RBD) of 2019 novel
coronavirus: implication for development of RBD protein as a viral attachment inhibitor
and vaccine</article-title>. <source>Cell Mol Immunol</source>.
<year>2020</year>;<volume>17(6)</volume>:<fpage>613</fpage>&#x02013;<lpage>620</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/s41423-020-0400-4</pub-id><pub-id pub-id-type="pmid">32203189</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madjid</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Safavi-Naeini</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Solomon</surname><given-names>SD</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Potential effects of coronaviruses on the cardiovascular system: A
Review</article-title>. <source>JAMA Cardiol</source>. <year>2020 Mar 27</year>. Online
ahead of print.</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>COVID-19 and the cardiovascular system</article-title>. <source>Nat Rev
Cardiol</source>.
<year>2020</year>;<volume>17</volume>:<fpage>259</fpage>&#x02013;<lpage>260</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/s41569-020-0360-5</pub-id><pub-id pub-id-type="pmid">32139904</pub-id></mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burrell</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>CI</given-names></name>, <name name-style="western"><surname>Tikellis</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>ACE2, a new regulator of the renin-angiotensin system</article-title>.
<source>Trends Endocrinol Metab</source>.
<year>2004</year>;<volume>15</volume>:<fpage>166</fpage>&#x02013;<lpage>169</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tem.2004.03.001</pub-id><pub-id pub-id-type="pmid">15109615</pub-id></mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qi</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Qian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Single cell RNA sequencing of 13 human tissues identify cell types and
receptors of human coronaviruses</article-title>. <source>Biochem Biophys Res
Commun</source>.
<year>2020</year>;<volume>526(1)</volume>:<fpage>135</fpage>&#x02013;<lpage>140</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.bbrc.2020.03.044</pub-id><pub-id pub-id-type="pmid">32199615</pub-id></mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9
virus-induced acute lung injury</article-title>. <source>Sci Rep</source>.
<year>2014</year>;<volume>4</volume>:<fpage>7027</fpage>. doi: <pub-id pub-id-type="doi">10.1038/srep07027</pub-id><pub-id pub-id-type="pmid">25391767</pub-id></mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1
infections</article-title>. <source>Nat Commun</source>.
<year>2014</year>;<volume>5</volume>:<fpage>3594</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms4594</pub-id><pub-id pub-id-type="pmid">24800825</pub-id></mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sodhi</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yamaguchi</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9)
bradykinin/BKB1R axis and facilitates LPS-induced neutrophil
infiltration</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>.
<year>2018</year>;<volume>314</volume>:<fpage>L17</fpage>&#x02013;<lpage>L31</lpage>. doi:
<pub-id pub-id-type="doi">10.1152/ajplung.00498.2016</pub-id><pub-id pub-id-type="pmid">28935640</pub-id></mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Khaidakov</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cross-talk between inflammation and angiotensin II: studies based on direct
transfection of cardiomyocytes with AT1R and AT2R cDNA</article-title>. <source>Exp Biol
Med (Maywood)</source>.
<year>2012</year>;<volume>237</volume>:<fpage>1394</fpage>&#x02013;<lpage>1401</lpage>. doi:
<pub-id pub-id-type="doi">10.1258/ebm.2012.012212</pub-id><pub-id pub-id-type="pmid">23354398</pub-id></mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues Prestes</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Rocha</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Miranda</surname><given-names>AS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The anti-inflammatory potential of ACE2/angiotensin-(1-7)/Mas receptor
axis: Evidence from Basic and clinical Research</article-title>. <source>Curr Drug
Targets</source>.
<year>2017</year>;<volume>18</volume>:<fpage>1301</fpage>&#x02013;<lpage>1313</lpage>. doi:
<pub-id pub-id-type="doi">10.2174/1389450117666160727142401</pub-id><pub-id pub-id-type="pmid">27469342</pub-id></mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Loss of ACE2 exacerbates murine renal ischemia-reperfusion
injury</article-title>. <source>PLoS One</source>.
<year>2013</year>;<volume>8</volume>:<fpage>e71433</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0071433</pub-id><pub-id pub-id-type="pmid">23951161</pub-id></mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>W</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sini decoction ameliorates sepsis-induced acute lung injury via regulating
ACE2-Ang (1-7)-Mas axis and inhibiting the MAPK signaling pathway</article-title>.
<source>Biomed Pharmacother</source>.
<year>2019</year>;<volume>115</volume>:<fpage>108971</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.biopha.2019.108971</pub-id><pub-id pub-id-type="pmid">31102910</pub-id></mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Song</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Oudit</surname><given-names>GY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1
expression, inflammation and peroxynitrite production</article-title>. <source>PLoS
One</source>. <year>2012</year>;<volume>7</volume>:<fpage>e38502</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0038502</pub-id><pub-id pub-id-type="pmid">22693641</pub-id></mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Xiao</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Renin-angiotensin system inhibitors improve the clinical outcomes of
COVID-19 patients with hypertension</article-title>. <source>Emerg Microbes
Infect</source>.
<year>2020</year>;<volume>9</volume>:<fpage>757</fpage>&#x02013;<lpage>760</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1746200</pub-id><pub-id pub-id-type="pmid">32228222</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Association of inpatient use of angiotensin converting enzyme inhibitors
and angiotensin II receptor blockers with mortality among patients with hypertension
hospitalized with COVID-19</article-title>. <source>Circ Res</source>.
<year>2020</year>;<volume>126(12)</volume>:<fpage>1671</fpage>&#x02013;<lpage>1681</lpage>. doi:
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317134</pub-id><pub-id pub-id-type="pmid">32302265</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rohrborn</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wronkowitz</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Eckel</surname><given-names>J.</given-names></name></person-group>
<article-title>DPP4 in diabetes</article-title>. <source>Front Immunol</source>.
<year>2015</year>;<volume>6</volume>:<fpage>386</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2015.00386</pub-id><pub-id pub-id-type="pmid">26284071</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meyerholz</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Lambertz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>McCray</surname><given-names>PB. Jr.</given-names></name></person-group>
<article-title>Dipeptidyl peptidase 4 distribution in the human respiratory tract:
Implications for the Middle East respiratory syndrome</article-title>. <source>Am J
Pathol</source>.
<year>2016</year>;<volume>186</volume>:<fpage>78</fpage>&#x02013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2015.09.014</pub-id><pub-id pub-id-type="pmid">26597880</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its
receptor CD26</article-title>. <source>Nature</source>.
<year>2013</year>;<volume>500</volume>:<fpage>227</fpage>&#x02013;<lpage>231</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/nature12328</pub-id><pub-id pub-id-type="pmid">23831647</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raj</surname><given-names>VS</given-names></name>, <name name-style="western"><surname>Mou</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Smits</surname><given-names>SL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human
coronavirus-EMC</article-title>. <source>Nature</source>.
<year>2013</year>;<volume>495</volume>:<fpage>251</fpage>&#x02013;<lpage>254</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/nature12005</pub-id><pub-id pub-id-type="pmid">23486063</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vankadari</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Wilce</surname><given-names>JA.</given-names></name></person-group>
<article-title>Emerging WuHan (COVID-19) coronavirus: glycan shield and structure
prediction of spike glycoprotein and its interaction with human CD26</article-title>.
<source>Emerg Microbes Infect</source>.
<year>2020</year>;<volume>9</volume>:<fpage>601</fpage>&#x02013;<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1739565</pub-id><pub-id pub-id-type="pmid">32178593</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus:
implications for virus origins and receptor binding</article-title>.
<source>Lancet</source>.
<year>2020</year>;<volume>395</volume>:<fpage>565</fpage>&#x02013;<lpage>574</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>GF.</given-names></name></person-group>
<article-title>Bat-to-human: spike features determining &#x02018;host jump&#x02019; of coronaviruses
SARS-CoV, MERS-CoV, and beyond</article-title>. <source>Trends Microbiol</source>.
<year>2015</year>;<volume>23</volume>:<fpage>468</fpage>&#x02013;<lpage>478</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.tim.2015.06.003</pub-id><pub-id pub-id-type="pmid">26206723</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Ni</surname><given-names>ZY</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Clinical Characteristics of coronavirus disease 2019 in
China</article-title>. <source>N Engl J Med</source>.
<year>2020</year>;<volume>382(18)</volume>:<fpage>1708</fpage>&#x02013;<lpage>1720</lpage>. doi:
<pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seys</surname><given-names>LJM</given-names></name>, <name name-style="western"><surname>Widagdo</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Verhamme</surname><given-names>FM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>DPP4, the Middle East respiratory syndrome coronavirus receptor, is
Upregulated in lungs of Smokers and chronic obstructive pulmonary disease
patients</article-title>. <source>Clinical Infectious Diseases: an Official Publication
of the Infectious Diseases Society of America</source>.
<year>2018</year>;<volume>66</volume>:<fpage>45</fpage>&#x02013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1093/cid/cix741</pub-id><pub-id pub-id-type="pmid">29020176</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klemann</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Stephan</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4)
entanglement in the immune system</article-title>. <source>Clin Exp Immunol</source>.
<year>2016</year>;<volume>185</volume>:<fpage>1</fpage>&#x02013;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1111/cei.12781</pub-id><pub-id pub-id-type="pmid">26919392</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hatano</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ohnuma</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Yamamoto</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>CD26-mediated co-stimulation in human CD8(+) T cells provokes effector
function via pro-inflammatory cytokine production</article-title>.
<source>Immunology</source>.
<year>2013</year>;<volume>138</volume>:<fpage>165</fpage>&#x02013;<lpage>172</lpage>. doi:
<pub-id pub-id-type="doi">10.1111/imm.12028</pub-id><pub-id pub-id-type="pmid">23113658</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitagawa</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Hamaguchi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Majima</surname><given-names>S</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dipeptidyl peptidase-4 inhibitors have adverse effects for the
proliferation of human T cells</article-title>. <source>J Clin Biochem Nutr</source>.
<year>2018</year>;<volume>63</volume>:<fpage>106</fpage>&#x02013;<lpage>112</lpage>. doi:
<pub-id pub-id-type="doi">10.3164/jcbn.17-64</pub-id><pub-id pub-id-type="pmid">30279621</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buhling</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Junker</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Reinhold</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Functional role of CD26 on human B lymphocytes</article-title>.
<source>Immunol Lett</source>.
<year>1995</year>;<volume>45</volume>:<fpage>47</fpage>&#x02013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0165-2478(94)00230-O</pub-id><pub-id pub-id-type="pmid">7622187</pub-id></mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Qahtani</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Lyroni</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Aznaourova</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Middle East respiratory syndrome corona virus spike glycoprotein suppresses
macrophage responses via DPP4-mediated induction of IRAK-M and
PPARgamma</article-title>. <source>Oncotarget</source>.
<year>2017</year>;<volume>8</volume>:<fpage>9053</fpage>&#x02013;<lpage>9066</lpage>. doi:
<pub-id pub-id-type="doi">10.18632/oncotarget.14754</pub-id><pub-id pub-id-type="pmid">28118607</pub-id></mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pinheiro</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Stoppa</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Valduga</surname><given-names>CJ</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17
differentiation in vitro</article-title>. <source>Eur J Pharm Sci</source>.
<year>2017</year>;<volume>100</volume>:<fpage>17</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejps.2016.12.040</pub-id><pub-id pub-id-type="pmid">28065853</pub-id></mixed-citation></ref><ref id="CIT0060"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aso</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fukushima</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sagara</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T
cells in patients with type 2 diabetes</article-title>. <source>Diabetes Res Clin
Pract</source>.
<year>2015</year>;<volume>110</volume>:<fpage>250</fpage>&#x02013;<lpage>256</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.diabres.2015.10.012</pub-id><pub-id pub-id-type="pmid">26508675</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nain</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Karmakar</surname><given-names>SP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>GRP78 is an important host factor for Japanese Encephalitis virus entry and
replication in Mammalian cells</article-title>. <source>J Virol</source>.
<year>2017</year>;<volume>91(6)</volume>:<fpage>e02274</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="pmid">28053106</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Triantafilou</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Fradelizi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>GRP78, a coreceptor for coxsackievirus A9, interacts with major
histocompatibility complex class I molecules which mediate virus
internalization</article-title>. <source>J Virol</source>.
<year>2002</year>;<volume>76</volume>:<fpage>633</fpage>&#x02013;<lpage>643</lpage>. doi:
<pub-id pub-id-type="doi">10.1128/JVI.76.2.633-643.2002</pub-id><pub-id pub-id-type="pmid">11752154</pub-id></mixed-citation></ref><ref id="CIT0063"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>AS.</given-names></name></person-group>
<article-title>Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic
potential</article-title>. <source>Nat Rev Cancer</source>.
<year>2014</year>;<volume>14</volume>:<fpage>263</fpage>&#x02013;<lpage>276</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/nrc3701</pub-id><pub-id pub-id-type="pmid">24658275</pub-id></mixed-citation></ref><ref id="CIT0064"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Abdelmalek</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Elfiky</surname><given-names>AA.</given-names></name></person-group>
<article-title>GRP78: a cell's response to stress</article-title>. <source>Life
Sci</source>.
<year>2019</year>;<volume>226</volume>:<fpage>156</fpage>&#x02013;<lpage>163</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.lfs.2019.04.022</pub-id><pub-id pub-id-type="pmid">30978349</pub-id></mixed-citation></ref><ref id="CIT0065"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>NQ</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>ZH</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>HX</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Glucose-regulated protein 78 demonstrates antiviral effects but is more
suitable for hepatocellular carcinoma prevention in hepatitis B</article-title>.
<source>Virol J</source>. <year>2017</year>;<volume>14</volume>:<fpage>77</fpage>. doi:
<pub-id pub-id-type="doi">10.1186/s12985-017-0747-z</pub-id><pub-id pub-id-type="pmid">28407787</pub-id></mixed-citation></ref><ref id="CIT0066"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Fung</surname><given-names>TS</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Upregulation of CHOP/GADD153 during coronavirus infectious bronchitis virus
infection modulates apoptosis by restricting activation of the extracellular
signal-regulated kinase pathway</article-title>. <source>J Virol</source>.
<year>2013</year>;<volume>87</volume>:<fpage>8124</fpage>&#x02013;<lpage>8134</lpage>. doi:
<pub-id pub-id-type="doi">10.1128/JVI.00626-13</pub-id><pub-id pub-id-type="pmid">23678184</pub-id></mixed-citation></ref><ref id="CIT0067"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Tseng</surname><given-names>CC</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Characterization and mechanism of stress-induced translocation of
78-kilodalton glucose-regulated protein (GRP78) to the cell surface</article-title>.
<source>J Biol Chem</source>.
<year>2015</year>;<volume>290</volume>:<fpage>8049</fpage>&#x02013;<lpage>8064</lpage>. doi:
<pub-id pub-id-type="doi">10.1074/jbc.M114.618736</pub-id><pub-id pub-id-type="pmid">25673690</pub-id></mixed-citation></ref><ref id="CIT0068"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>CP</given-names></name>, <name name-style="western"><surname>Siu</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Chin</surname><given-names>KT</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Modulation of the unfolded protein response by the severe acute respiratory
syndrome coronavirus spike protein</article-title>. <source>J Virol</source>.
<year>2006</year>;<volume>80</volume>:<fpage>9279</fpage>&#x02013;<lpage>9287</lpage>. doi:
<pub-id pub-id-type="doi">10.1128/JVI.00659-06</pub-id><pub-id pub-id-type="pmid">16940539</pub-id></mixed-citation></ref><ref id="CIT0069"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>IM</given-names></name>, <name name-style="western"><surname>Abdelmalek</surname><given-names>DH</given-names></name>, <name name-style="western"><surname>Elshahat</surname><given-names>ME</given-names></name>, <etal>et al.</etal></person-group>
<article-title>COVID-19 spike-host cell receptor GRP78 binding site
prediction</article-title>. <source>J Infect</source>.
<year>2020</year>;<volume>80</volume>:<fpage>554</fpage>&#x02013;<lpage>562</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/j.jinf.2020.02.026</pub-id><pub-id pub-id-type="pmid">32169481</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name></person-group>
<article-title>Diagnosis and clinical management of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union
medical College Hospital (V2.0)</article-title>. <source>Emerg Microbes Infect</source>.
<year>2020</year>;<volume>9</volume>:<fpage>582</fpage>&#x02013;<lpage>585</lpage>. doi: <pub-id pub-id-type="doi">10.1080/22221751.2020.1735265</pub-id><pub-id pub-id-type="pmid">32172669</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group>
<article-title>Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms
to potential therapeutic Tools</article-title>. <source>Virol Sin</source>. <year>2020
Mar 3</year>;1&#x02013;6. Online ahead of print.</mixed-citation></ref><ref id="CIT0072"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beigel</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Tomashek</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Dodd</surname><given-names>LE</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Remdesivir for the treatment of covid-19 - Preliminary
Report</article-title>. <source>N Engl J Med</source>. <year>2020 May 22</year>. Online
ahead of print.</mixed-citation></ref><ref id="CIT0073"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferner</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Aronson</surname><given-names>JK.</given-names></name></person-group>
<article-title>Remdesivir in covid-19</article-title>. <source>Br Med J</source>.
<year>2020</year>;<volume>369</volume>:<fpage>m1610</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.m1610</pub-id><pub-id pub-id-type="pmid">32321732</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ledford</surname><given-names>H.</given-names></name></person-group>
<article-title>Hopes rise for coronavirus drug remdesivir</article-title>.
<source>Nature</source>. <year>2020 Apr 29</year>. Online ahead of
print.</mixed-citation></ref><ref id="CIT0075"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>G</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind,
placebo-controlled, multicentre trial</article-title>. <source>Lancet</source>.
<year>2020</year>;<volume>395</volume>:<fpage>1569</fpage>&#x02013;<lpage>1578</lpage>. doi:
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31022-9</pub-id><pub-id pub-id-type="pmid">32423584</pub-id></mixed-citation></ref><ref id="CIT0076"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qaseem</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Yost</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Etxeandia-Ikobaltzeta</surname><given-names>I</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Should Clinicians Use chloroquine or Hydroxychloroquine Alone or in
Combination With Azithromycin for the Prophylaxis or treatment of
COVID-19?</article-title>
<source>Ann Intern Med</source>. <year>2020 May 13</year>. Online ahead of
print.</mixed-citation></ref><ref id="CIT0077"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borba</surname><given-names>MGS</given-names></name>, <name name-style="western"><surname>Val</surname><given-names>FFA</given-names></name>, <name name-style="western"><surname>Sampaio</surname><given-names>VS</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effect of high vs low doses of chloroquine Diphosphate as Adjunctive
therapy for patients hospitalized With severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection: A Randomized clinical trial</article-title>. <source>JAMA
Network Open</source>. <year>2020</year>;<volume>3</volume>:<fpage>e208857</fpage>. doi:
<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Principi</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name></person-group>
<article-title>Chloroquine or hydroxychloroquine for prophylaxis of
COVID-19</article-title>. <source>Lancet Infect Dis</source>.
<year>2020</year>;<volume>S1473-3099(20)30296-6</volume>.</mixed-citation></ref><ref id="CIT0079"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakhar</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>I.</given-names></name></person-group>
<article-title>Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes
fears of shortages among people with systemic lupus erythematosus</article-title>.
<source>Nat Med</source>. <year>2020</year>;<volume>26</volume>:<fpage>632</fpage>. doi:
<pub-id pub-id-type="doi">10.1038/s41591-020-0853-0</pub-id></mixed-citation></ref><ref id="CIT0080"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazdany</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>AHJ.</given-names></name></person-group>
<article-title>Use of Hydroxychloroquine and chloroquine during the COVID-19 pandemic:
What Every Clinician should Know</article-title>. <source>Ann Intern Med</source>.
<year>2020</year>;<volume>172(11)</volume>:<fpage>754</fpage>&#x02013;<lpage>755</lpage>. doi:
<pub-id pub-id-type="doi">10.7326/M20-1334</pub-id><pub-id pub-id-type="pmid">32232419</pub-id></mixed-citation></ref><ref id="CIT0081"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel
coronavirus (2019-nCoV) in vitro</article-title>. <source>Cell Res</source>.
<year>2020</year>;<volume>30</volume>:<fpage>269</fpage>&#x02013;<lpage>271</lpage>. doi:
<pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="CIT0082"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irwin</surname><given-names>KK</given-names></name>, <name name-style="western"><surname>Renzette</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kowalik</surname><given-names>TF</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antiviral drug resistance as an adaptive process</article-title>.
<source>Virus Evol</source>. <year>2016</year>;<volume>2</volume>:<fpage>vew014</fpage>.
doi: <pub-id pub-id-type="doi">10.1093/ve/vew014</pub-id><pub-id pub-id-type="pmid">28694997</pub-id></mixed-citation></ref><ref id="CIT0083"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boas LCP</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Campos</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Berlanda</surname><given-names>RLA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Antiviral peptides as promising therapeutic drugs</article-title>.
<source>Cell Mol Life Sci</source>.
<year>2019</year>;<volume>76</volume>:<fpage>3525</fpage>&#x02013;<lpage>3542</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/s00018-019-03138-w</pub-id><pub-id pub-id-type="pmid">31101936</pub-id></mixed-citation></ref><ref id="CIT0084"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Marsh</surname><given-names>M.</given-names></name></person-group>
<article-title>Targeting viral entry as a strategy for broad-spectrum
antivirals</article-title>. <source>F1000Res</source>.
<year>2019</year>;<volume>8</volume>:<fpage>1628</fpage>. doi: <pub-id pub-id-type="doi">10.12688/f1000research.19694.1</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobrovolny</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Beauchemin</surname><given-names>CAA.</given-names></name></person-group>
<article-title>Modelling the emergence of influenza drug resistance: The roles of surface
proteins, the immune response and antiviral mechanisms</article-title>. <source>PLoS
One</source>. <year>2017</year>;<volume>12</volume>:<fpage>e0180582</fpage>. doi:
<pub-id pub-id-type="doi">10.1371/journal.pone.0180582</pub-id><pub-id pub-id-type="pmid">28700622</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotte</surname><given-names>M.</given-names></name></person-group>
<article-title>The distinct contributions of fitness and genetic barrier to the
development of antiviral drug resistance</article-title>. <source>Curr Opin
Virol</source>.
<year>2012</year>;<volume>2</volume>:<fpage>644</fpage>&#x02013;<lpage>650</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coviro.2012.08.004</pub-id><pub-id pub-id-type="pmid">22964133</pub-id></mixed-citation></ref><ref id="CIT0087"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Network-based drug repurposing for novel coronavirus
2019-nCoV/SARS-CoV-2</article-title>. <source>Cell Discov</source>.
<year>2020</year>;<volume>6</volume>:<fpage>14</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41421-020-0153-3</pub-id><pub-id pub-id-type="pmid">32194980</pub-id></mixed-citation></ref><ref id="CIT0088"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ilan</surname><given-names>Y.</given-names></name></person-group>
<article-title>Generating randomness: making the most out of disordering a false order
into a real one</article-title>. <source>J Transl Med</source>.
<year>2019</year>;<volume>17</volume>:<fpage>49</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12967-019-1798-2</pub-id><pub-id pub-id-type="pmid">30777074</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Haj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kanovitch</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ilan</surname><given-names>Y.</given-names></name></person-group>
<article-title>Personalized inherent randomness of the immune system is manifested by an
individualized response to immune triggers and immunomodulatory therapies: a novel
platform for designing personalized immunotherapies</article-title>. <source>Immunol
Res</source>.
<year>2019</year>;<volume>67</volume>:<fpage>337</fpage>&#x02013;<lpage>347</lpage>. doi:
<pub-id pub-id-type="doi">10.1007/s12026-019-09101-y</pub-id><pub-id pub-id-type="pmid">31754971</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elgart</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Loscalzo</surname><given-names>J.</given-names></name></person-group>
<article-title>Determinants of drug-target interactions at the single cell
level</article-title>. <source>PLoS Comput Biol</source>.
<year>2018</year>;<volume>14</volume>:<fpage>e1006601</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pcbi.1006601</pub-id><pub-id pub-id-type="pmid">30571695</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Contin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Alberghini</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Candela</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intrapatient variation in antiepileptic drug plasma concentration after
generic substitution vs stable brand-name drug regimens</article-title>.
<source>Epilepsy Res</source>.
<year>2016</year>;<volume>122</volume>:<fpage>79</fpage>&#x02013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2016.02.012</pub-id><pub-id pub-id-type="pmid">26987080</pub-id></mixed-citation></ref><ref id="CIT0092"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kenig</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ilan</surname><given-names>Y.</given-names></name></person-group>
<article-title>A personalized Signature and chronotherapy-based platform for improving the
efficacy of sepsis treatment</article-title>. <source>Front Physiol</source>.
<year>2019</year>;<volume>10</volume>:<fpage>1542</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2019.01542</pub-id><pub-id pub-id-type="pmid">31920730</pub-id></mixed-citation></ref><ref id="CIT0093"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khoury</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ilan</surname><given-names>Y.</given-names></name></person-group>
<article-title>Introducing patterns of variability for overcoming compensatory adaptation
of the immune system to immunomodulatory agents: a novel method for improving clinical
response to anti-TNF therapies</article-title>. <source>Front Immunol</source>.
<year>2019</year>;<volume>10</volume>:<fpage>2726</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.02726</pub-id><pub-id pub-id-type="pmid">31824506</pub-id></mixed-citation></ref><ref id="CIT0094"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strik</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Berends</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Mould</surname><given-names>DR</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dashboard driven vs. conventional dosing of infliximab in inflammatory
bowel disease patients: the PRECISION trial</article-title>. <source>Journal of Crohn's
and Colitis</source>. <year>2019</year>;<volume>13</volume>:<fpage>S063</fpage>
<comment>(Abstract)</comment>. doi: <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjy222.090</pub-id></mixed-citation></ref></ref-list></back></article>